No Data
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Is Largely Controlled by Institutional Shareholders Who Own 69% of the Company
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $45
Arrowhead Wraps Enrollment for 3 Key Trials on Fat-Busting Drug, Eyes FDA Decision in November
Express News | Arrowhead Pharmaceuticals Inc - FDA Sets Pdufa Date for Plozasiran Nda on November 18, 2025
Express News | Arrowhead Pharmaceuticals Inc - Study Completion Expected Mid-2026 With Data Readout to Follow
Express News | Arrowhead Pharmaceuticals : Bernstein Cuts Target Price to $17 From $24